CADL Quote, Financials, Valuation and Earnings

Bristol-Myers Squibb has a net margin of -- compared to Candel Therapeutics's net margin of 10.18%. Candel Therapeutics's return on equity of -- beat Bristol-Myers Squibb's return on equity of -33.18%.

Candel Therapeutics has a consensus price target of $19.00, signalling upside risk potential of 115.91%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $60.91 which suggests that it could grow by 5.45%. Given that Candel Therapeutics has higher upside potential than Bristol-Myers Squibb, analysts believe Candel Therapeutics is more attractive than Bristol-Myers Squibb.

Candel Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.454, suggesting its less volatile than the S&P 500 by 54.628%.

Candel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 4.16% to investors and pays a quarterly dividend of $0.60 per share. Candel Therapeutics pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out 59.12% of its earnings as a dividend. Bristol-Myers Squibb's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Candel Therapeutics quarterly revenues are --, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.9B. Candel Therapeutics's net income of -$10.6M is lower than Bristol-Myers Squibb's net income of $1.2B. Notably, Candel Therapeutics's price-to-earnings ratio is -- while Bristol-Myers Squibb's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics is 2,130.29x versus 2.47x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -- compared to Candel Therapeutics's net margin of -31993.31%. Candel Therapeutics's return on equity of -- beat Inovio Pharmaceuticals's return on equity of -98.72%.

Candel Therapeutics has a consensus price target of $19.00, signalling upside risk potential of 115.91%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $10.67 which suggests that it could grow by 482.88%. Given that Inovio Pharmaceuticals has higher upside potential than Candel Therapeutics, analysts believe Inovio Pharmaceuticals is more attractive than Candel Therapeutics.

Candel Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 0.749, suggesting its less volatile than the S&P 500 by 25.086%.

Candel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Candel Therapeutics pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Candel Therapeutics quarterly revenues are --, which are smaller than Inovio Pharmaceuticals quarterly revenues of $100.8K. Candel Therapeutics's net income of -$10.6M is higher than Inovio Pharmaceuticals's net income of -$25.2M. Notably, Candel Therapeutics's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics is 2,130.29x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Candel Therapeutics's net margin of -49.65%. Candel Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Candel Therapeutics has a consensus price target of $19.00, signalling upside risk potential of 115.91%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than Candel Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Candel Therapeutics.

Candel Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Candel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Candel Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Candel Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Candel Therapeutics's net income of -$10.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Candel Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics is 2,130.29x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Candel Therapeutics's net margin of 25.23%. Candel Therapeutics's return on equity of -- beat Pfizer's return on equity of 4.63%.

Candel Therapeutics has a consensus price target of $19.00, signalling upside risk potential of 115.91%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.16%. Given that Candel Therapeutics has higher upside potential than Pfizer, analysts believe Candel Therapeutics is more attractive than Pfizer.

Candel Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Candel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.28% to investors and pays a quarterly dividend of $0.42 per share. Candel Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Candel Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.7B. Candel Therapeutics's net income of -$10.6M is lower than Pfizer's net income of $4.5B. Notably, Candel Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics is 2,130.29x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.